Status:
UNKNOWN
Efficacy and Safety of Timolol for TKI Induced Paronychia
Lead Sponsor:
Queen Mary Hospital, Hong Kong
Conditions:
Paronychia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study would assess the clinical efficacy of add-on topical timolol 0.5% gel to betamethasone valerate 0.1% for the treatment of EGFR-TKI induced paronychia. Eligible patients, who develop paronyc...
Detailed Description
The aim of this study ist o assess the clinical efficacy of add-on topical timolol 0.5% gel to betamethasone valerate 0.1% for the treatment of EGFR-TKI induced paronychia.
Eligibility Criteria
Inclusion
- Aged 18 years or above, either males or females.
- Received EGFR-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib and mobocertinib.
- Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use.
- Written informed consent obtained from patient.
Exclusion
- Age below18.
- Patients who are allergic to, or contraindicated to topical timolol use.
- Pregnant women or nursing mother.
- Non-consenting patients.
Key Trial Info
Start Date :
April 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06140186
Start Date
April 1 2023
End Date
March 31 2024
Last Update
December 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong